Completion of a Study to Define the Natural History of CADASIL, a Rare Genetic Disease

The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), has successfully completed a longitudinal observational study (NCT02821780) involving 20 patients with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), a disease caused by mutations in the NOTCH3 gene. Initiated in 2016 and lasting approximately six years, this study systematically quantified the natural history and microvascular pathophysiology of this ultra-rare cerebrovascular disease, offering significant academic value. The research team, led by Dr. Manfred Boehm, focused on elucidating the mechanisms of vascular smooth muscle cell (vSMC) dysfunction and chronic hypoperfusion. This is expected to serve as essential preclinical data for the development of fundamental therapeutic pipelines, such as gene therapies.

Securing a Non-Invasive Biomarker through Retinal Vascular Dysfunction

The research team published groundbreaking findings in the March 2026 issue of the medical journal Neurology® Open Access, analyzing retinal vascular imaging data from CADASIL patients. The results revealed significant retinal vascular dysfunction in 19 CADASIL patients compared to a control group of 9 healthy individuals. Previously, directly measuring the extent of damage to the deep microvasculature of the brain was nearly impossible. However, this study scientifically demonstrates that retinal vessels reflect the condition of cerebral blood vessels. Consequently, clinical development companies now have a non-invasive biomarker assessment tool, retinal imaging, to replace brain biopsies or costly MRIs.

Presenting a New Milestone in the Design of Clinical Trials for New Drugs

The identified retinal microvascular assessment is expected to bring innovative changes to the design of clinical trial efficacy evaluations for CADASIL therapies. Due to the slow progression of cerebrovascular diseases over decades, it has been challenging to objectively demonstrate the efficacy of drugs in short-term clinical trials. However, by establishing precise functional changes in retinal blood vessels as an efficacy evaluation indicator before and after drug administration, clinical trial periods can be significantly shortened, and the required patient population can be optimized. This will create an environment where global pharmaceutical companies and small biotech firms can reduce clinical failure risks and invest more boldly in CADASIL pipelines.

Commercial Value in a Rare Disease Market with Maximized Unmet Needs

CADASIL is a rare disease with a prevalence of approximately 2-5 cases per 100,000 people worldwide, but the potential number of individuals carrying NOTCH3 mutations is estimated to be 3.4 per 1,000, suggesting a large undiagnosed patient population. The current lack of disease-modifying therapies, with patients relying solely on palliative care, provides new drug development companies with exclusive commercial opportunities. Examples include RUNX1 small molecule modulators, such as 'X101' developed by X1 Biotech, and mutant protein aggregation-inhibiting immunotherapies from the Karolinska Institutet, which are actively being researched in preclinical stages. The biomarker system established through this clinical trial will serve as an organic bridge, accelerating the entry of these competing pipelines into Phase 1 and Phase 2 clinical trials.